Versartis Inc. Cmn (VSAR) 10.75 $VSAR
Versartis Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 3:05PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the second quarter ended June 30, 2016 and provided an update on its clinical development programs.
VSAR: 10.75 (-0.49)
Versartis Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2016.
VSAR: 10.75 (-0.49)
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)
5 Stocks with Rising Analyst Coverage
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 3:54PM CDT
New or increased coverage on a stock is usually the result of huge investor focus on it.
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)
Versartis (VSAR) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:51AM CDT
As of late, it has definitely been a great time to be an investor in Versartis Inc (VSAR)
VSAR: 10.75 (-0.49)
Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Mon Apr 04, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that Year 2 safety and efficacy data from its ongoing Extension Study of somavaratan in children with GHD were presented yesterday in a late-breaker oral presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. George Bright, MD, Versartis' Global Pediatric Clinical Development Advisor, presented the results at the late breaker oral session (LB-OR02-2) titled "Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years" on Sunday, April 3, 2016.
VSAR: 10.75 (-0.49)
Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Fri Apr 01, 6:00AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that adherence data from its ongoing Extension Study of somavaratan in children with GHD will be presented today in a late-breaker poster presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. Eric Humphriss, MBA, Vice President of Clinical Operations at Versartis, will discuss the results at the Late Breaker poster session (poster LBFri-01) on Friday, April 1, 2016 from 1:15 p.m. - 3:15 p.m. Eastern Time (ET).
VSAR: 10.75 (-0.49)
Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer
GlobeNewswire - Wed Mar 30, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it has appointed Colin Hislop, M.D. as Chief Medical Officer. Dr. Hislop is an experienced drug development clinician with over 27 years of experience in both pharmaceutical and biotechnology companies.
VSAR: 10.75 (-0.49)
Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society's 98th Annual Meeting
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that detailed two-year, safety, efficacy and adherence data from its ongoing Extension Study of somavaratan in children with GHD will be featured in two late-breaker presentations at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), to be held April 1-4, 2016, in Boston, MA. The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children.
VSAR: 10.75 (-0.49)
Capella Bioscience Completes Series A Financing of GBP11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire Europe - Tue Mar 08, 3:01AM CST
LONDON, March 8, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire - Tue Mar 08, 3:00AM CST
Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company's novel therapeutic antibody discovery programs towards clinical evaluation.
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a EUR210m Fund including GSK and Johnson & Johnson Innovation
PR Newswire Europe - Tue Feb 02, 12:01AM CST
LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan
GlobeNewswire - Thu Jan 28, 3:05PM CST
Conference Call and Webcast Featuring Guest Speaker Dr. Bradley Miller Scheduled at 7:30 a.m. ET on February 2, 2016
VSAR: 10.75 (-0.49)
Versartis' VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism
GlobeNewswire - Wed Dec 16, 12:38PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that results of a Phase 1b/2a pediatric trial of the investigational drug, somavaratan, were published online in The Journal of Clinical Endocrinology & Metabolism (JCEM) entitled "A Randomized Safety and Efficacy Study of somavaratan, a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency" .
VSAR: 10.75 (-0.49)
Direction of Market Influences - Analyst Notes on Maxwell Technologies, Organovo Holdings, Abraxas Petroleum and Versartis
ACCESSWIRE - Wed Dec 16, 7:26AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Maxwell Technologies Inc. (NASDAQ: MXWL), Organovo Holdings Inc. (NYSE: ONVO), Abraxas Petroleum Corp (NASDAQ: AXAS) and Versartis Inc. (NASDAQ: VSAR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MXWL: 5.25 (-0.07), VSAR: 10.75 (-0.49), ONVO: 4.20 (-0.17), AXAS: 1.11 (-0.01)
Growth Hormone Deficiency - Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cpvstr/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Ascendis Pharma A/S - Biogenomics Limited - Bolder Biotechnology, Inc. - Braasch Biotech LLC - Carlina Technologies SAS - Critical Pharmaceuticals Limited - Delpor, Inc. - Flamel Technologies S.A. - Genexine, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Inbiopro Solutions Pvt. Ltd. - JCR Pharmaceuticals Co., Ltd. - LG Life Sciences Limited - OPKO Health, Inc. - Pfenex Inc. - Prometheon Pharma, LLC - Teva Pharmaceutical Industries Limited - Versartis, Inc. - XL-protein GmbH For more information visit http://www.researchandmarkets.com/research/cp...th_hormone
VSAR: 10.75 (-0.49), FLML: 12.53 (-0.11), ASND: 13.96 (-0.11), OPK: 9.90 (-0.17), TEVA: 53.20 (-0.41), PFNX: 8.49 (-0.11)
Versartis to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 3:16PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Mr. Jay Shepard, President and Chief Executive Officer, is scheduled to present at the Credit Suisse 24 Annual Healthcare Conference on Tuesday, November 10 in Scottsdale, Arizona.
VSAR: 10.75 (-0.49)
Versartis reports 3Q loss
Automated Insights - Thu Oct 29, 5:31PM CDT
MENLO PARK, Calif. (AP) _ Versartis Inc. (VSAR) on Thursday reported a loss of $20.4 million in its third quarter.
VSAR: 10.75 (-0.49)
Versartis Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Oct 29, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the third quarter and nine months ended September 30, 2015.
VSAR: 10.75 (-0.49)
Versartis Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 3:05PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the second quarter ended June 30, 2016 and provided an update on its clinical development programs.
VSAR: 10.75 (-0.49)
Versartis Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the first quarter ended March 31, 2016.
VSAR: 10.75 (-0.49)
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)
5 Stocks with Rising Analyst Coverage
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 3:54PM CDT
New or increased coverage on a stock is usually the result of huge investor focus on it.
VSAR: 10.75 (-0.49), IBKR: 34.46 (-0.67), AXDX: 19.98 (-0.54), ONCE: 55.96 (-2.91), YRD: 25.44 (-2.86)
Versartis (VSAR) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:51AM CDT
As of late, it has definitely been a great time to be an investor in Versartis Inc (VSAR)
VSAR: 10.75 (-0.49)
Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Mon Apr 04, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that Year 2 safety and efficacy data from its ongoing Extension Study of somavaratan in children with GHD were presented yesterday in a late-breaker oral presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. George Bright, MD, Versartis' Global Pediatric Clinical Development Advisor, presented the results at the late breaker oral session (LB-OR02-2) titled "Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): Results at 2 Years" on Sunday, April 3, 2016.
VSAR: 10.75 (-0.49)
Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting
GlobeNewswire - Fri Apr 01, 6:00AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that adherence data from its ongoing Extension Study of somavaratan in children with GHD will be presented today in a late-breaker poster presentation at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), in Boston, MA. Eric Humphriss, MBA, Vice President of Clinical Operations at Versartis, will discuss the results at the Late Breaker poster session (poster LBFri-01) on Friday, April 1, 2016 from 1:15 p.m. - 3:15 p.m. Eastern Time (ET).
VSAR: 10.75 (-0.49)
Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer
GlobeNewswire - Wed Mar 30, 7:30AM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it has appointed Colin Hislop, M.D. as Chief Medical Officer. Dr. Hislop is an experienced drug development clinician with over 27 years of experience in both pharmaceutical and biotechnology companies.
VSAR: 10.75 (-0.49)
Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society's 98th Annual Meeting
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that detailed two-year, safety, efficacy and adherence data from its ongoing Extension Study of somavaratan in children with GHD will be featured in two late-breaker presentations at the Endocrine Society's 98th Annual Meeting & Expo (ENDO 2016), to be held April 1-4, 2016, in Boston, MA. The Extension Study is a long-term safety study that was initiated in March 2014 as patients completed the Phase 1b/2a clinical trial evaluating somavaratan therapy in treatment-naive, pre-pubertal GHD children.
VSAR: 10.75 (-0.49)
Capella Bioscience Completes Series A Financing of GBP11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire Europe - Tue Mar 08, 3:01AM CST
LONDON, March 8, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline
PR Newswire - Tue Mar 08, 3:00AM CST
Capella Bioscience Ltd. announced today the close of a £11 million ($15.5 million), Series A financing round. The round was financed by Advent Life Sciences, Medicxi Ventures, and Osage University Partners. The new capital will support continued advancement of the company's novel therapeutic antibody discovery programs towards clinical evaluation.
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a EUR210m Fund including GSK and Johnson & Johnson Innovation
PR Newswire Europe - Tue Feb 02, 12:01AM CST
LONDON, GENEVA and JERSEY, February 2, 2016 /PRNewswire/ --
VSAR: 10.75 (-0.49), EGLT: 6.93 (-0.09), NERV: 10.79 (-0.39)
Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan
GlobeNewswire - Thu Jan 28, 3:05PM CST
Conference Call and Webcast Featuring Guest Speaker Dr. Bradley Miller Scheduled at 7:30 a.m. ET on February 2, 2016
VSAR: 10.75 (-0.49)
Versartis' VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism
GlobeNewswire - Wed Dec 16, 12:38PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that results of a Phase 1b/2a pediatric trial of the investigational drug, somavaratan, were published online in The Journal of Clinical Endocrinology & Metabolism (JCEM) entitled "A Randomized Safety and Efficacy Study of somavaratan, a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency" .
VSAR: 10.75 (-0.49)
Direction of Market Influences - Analyst Notes on Maxwell Technologies, Organovo Holdings, Abraxas Petroleum and Versartis
ACCESSWIRE - Wed Dec 16, 7:26AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Maxwell Technologies Inc. (NASDAQ: MXWL), Organovo Holdings Inc. (NYSE: ONVO), Abraxas Petroleum Corp (NASDAQ: AXAS) and Versartis Inc. (NASDAQ: VSAR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MXWL: 5.25 (-0.07), VSAR: 10.75 (-0.49), ONVO: 4.20 (-0.17), AXAS: 1.11 (-0.01)
Growth Hormone Deficiency - Pipeline Review 2015
M2 - Fri Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cpvstr/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Ascendis Pharma A/S - Biogenomics Limited - Bolder Biotechnology, Inc. - Braasch Biotech LLC - Carlina Technologies SAS - Critical Pharmaceuticals Limited - Delpor, Inc. - Flamel Technologies S.A. - Genexine, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Inbiopro Solutions Pvt. Ltd. - JCR Pharmaceuticals Co., Ltd. - LG Life Sciences Limited - OPKO Health, Inc. - Pfenex Inc. - Prometheon Pharma, LLC - Teva Pharmaceutical Industries Limited - Versartis, Inc. - XL-protein GmbH For more information visit http://www.researchandmarkets.com/research/cp...th_hormone
VSAR: 10.75 (-0.49), FLML: 12.53 (-0.11), ASND: 13.96 (-0.11), OPK: 9.90 (-0.17), TEVA: 53.20 (-0.41), PFNX: 8.49 (-0.11)
Versartis to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 3:16PM CST
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Mr. Jay Shepard, President and Chief Executive Officer, is scheduled to present at the Credit Suisse 24 Annual Healthcare Conference on Tuesday, November 10 in Scottsdale, Arizona.
VSAR: 10.75 (-0.49)
Versartis reports 3Q loss
Automated Insights - Thu Oct 29, 5:31PM CDT
MENLO PARK, Calif. (AP) _ Versartis Inc. (VSAR) on Thursday reported a loss of $20.4 million in its third quarter.
VSAR: 10.75 (-0.49)
Versartis Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Oct 29, 3:06PM CDT
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the third quarter and nine months ended September 30, 2015.
VSAR: 10.75 (-0.49)
